Citation

Bonnet U. CNS Drug Rev. 2002; 8(3): 283-308.

Affiliation

Rheinische Kliniken Essen, Department of Psychiatry and Psycotherapy, University of Essen, Essen, Germany. udo.bonnet@uni-essen.de.

Copyright

(Copyright © 2002, Neva Press, Inc)

DOI

unavailable

PMID

12353059

Abstract

The benzamide moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively in anxiety disorders. While clinical aspects will be presented in a subsequent review, this article focuses primarily on moclobemide's evolution, pharmacodynamic and pharmacokinetic properties. In particular, the effects on neurotransmission and intracellular signal transduction, the neuroendocrine system, the tyramine pressure response and animal models of depression are surveyed. In addition, other CNS effects are reviewed with special respect to experimental serotonergic syndrome, anxiolytic and antinociceptive activity, sleep, cognition and driving performance, neuroprotection and seizures.

Language: en